X4 Pharmaceuticals trial results could support FDA approval for mavorixafor
1 report, 1 independent
Updated Fri 00:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Adam Craig stated that positive results from the Phase III 4WARD trial of mavorixafor could support potential U.S. Food and Drug Administration approval in late 2028 or early 2029. The company running the trial expects to complete enrollment by the end of the fourth quarter of 2026, with top-line data anticipated in the first quarter of 2028.
From dailypolitical.com
Why it matters
The trial is evaluating mavorixafor, a CXCR4 antagonist, for primary chronic neutropenia. Approval would determine the market viability and availability of this treatment for patients with chronic neutropenia.
From dailypolitical.com
Who's involved
- Adam CraigExecutive Chairman who provided the update on the trial results
- FDARegulatory body that would determine product viability and market access
Keep exploring
The entities involved
-
Adam Craig
American cyclist
Nothing else this week.
- FDA
Related events
- FDA approval is the goal for product candidates from Daré Bioscience, Inc.
- Research advances have led to the approval of new therapies by the FDA.
- FDA approved a medical device from Abbott and supported a PARADIGM study based on data from the Cleveland Clinic.
- FDA approval supports NDA submission in Aurora.
- Merck announced on September 3, 2025, that it is seeking potential approval for new drugs from the FDA.